Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare Fresenius SE & Co. to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, earnings, dividends, profitability and valuation.
Analyst Recommendations
This is a breakdown of current ratings for Fresenius SE & Co. and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fresenius SE & Co. | 0 | 0 | 3 | 0 | 3.00 |
| Fresenius SE & Co. Competitors | 4309 | 10596 | 18377 | 837 | 2.46 |
As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.33%. Given Fresenius SE & Co.’s competitors higher probable upside, analysts clearly believe Fresenius SE & Co. has less favorable growth aspects than its competitors.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Fresenius SE & Co. | 6.58% | 10.24% | 4.94% |
| Fresenius SE & Co. Competitors | -270.28% | -155.47% | -22.38% |
Volatility & Risk
Fresenius SE & Co. has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Fresenius SE & Co.’s competitors have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.
Insider and Institutional Ownership
40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Fresenius SE & Co. and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fresenius SE & Co. | $25.87 billion | $1.43 billion | 18.50 |
| Fresenius SE & Co. Competitors | $1.87 billion | $136.27 million | 5.73 |
Fresenius SE & Co. has higher revenue and earnings than its competitors. Fresenius SE & Co. is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Dividends
Fresenius SE & Co. pays an annual dividend of $0.20 per share and has a dividend yield of 1.4%. Fresenius SE & Co. pays out 25.0% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.1% and pay out 40.5% of their earnings in the form of a dividend.
Summary
Fresenius SE & Co. beats its competitors on 9 of the 15 factors compared.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain. Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
